Active Ingredient History
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 2)
BRCA1 Protein (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Glioblastoma (Phase 1/Phase 2)
Hamartoma (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1/Phase 2)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)
Meningioma (Phase 2)
Mutation (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neurofibromatosis 2 (Phase 2)
Ovarian Neoplasms (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 1)
Small Cell Lung Carcinoma (Phase 2)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 1)
Uterine Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue